Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Embecta Corp.NASDAQ: EMBC

Cost of Revenue · Q2 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q2 FY2026 cost of revenue of $96.6M fell 0.9% year over year, behind the -0.3% change in trailing-twelve-month cost of revenue. Sequentially, it rose 12.9% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.

Context

  • Cost of revenue amounted to 37.1% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.9% toward the trailing-twelve-month pace of -0.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$96.6M+12.9% QoQ
Last fiscal yearSep 2025
$400.9M+1.7% YoY
LTMMar 2026
$390.7M-0.3% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%——
1 year+1.7%——
3-year CAGR+4.2%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
400.9M USD
Year-over-year change
+1.7%
4-year CAGR
+2.4%

Cost of Revenue vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 cost of revenue of $390.7M is the 2nd highest of the 11 companies compared; the peer median is $95.21M.
  • Its year-over-year change of -0.3% is the 5th highest of 10, against a peer median of -2.6%.
  • Cost of revenue amounts to 37.5% of revenue for EMBC, versus a peer median of 60.5%.
EMBC Competitors Peer median
Cost of Revenue for EMBC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EVHEvolent Health, Inc.LTM Mar 2026$1.62B -20.2%+15.4%85.9%
EMBCEmbecta Corp.LTM Mar 2026$390.7M -0.3%+4.2%37.5%
EBSEmergent BioSolutions Inc.LTM Mar 2026$376M -38.7%-15.3%55.6%
MYGNMyriad Genetics, Inc.LTM Mar 2026$249M -0.1%+7.1%30.0%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$136.53M -10.8%-3.4%65.4%
CDNACareDx, IncLTM Jun 2026$134.76M +19.4%+3.2%29.4%
PSNLPersonalis, Inc.LTM Mar 2026$55.67M -2.6%+1.4%86.3%
PRMEPrime Medicine, Inc.LTM Mar 2026$47.71M ——1182.7%
SIGASIGA Technologies, Inc.LTM Mar 2026$32.49M +15.1%+41.7%34.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$18.37M +7.2%-4.0%36.5%
VIRVir Biotechnology, Inc.LTM Mar 2026-$114.78M -122.6%-73.4%175.2%
Peer median (excluding EMBC) $95.21M-2.6%+1.4%60.5%

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue1.17B1.13B1.12B1.12B1.08B
Cost of Revenue365M354.6M370.9M394.2M400.9M
Gross Profit800M774.9M749.9M728.9M679.5M
Gross Margin68.7%68.6%66.9%64.9%62.9%
Research & Development63M65M85.2M78.8M21.5M
Selling, General & Admin240.3M294.8M341.3M365.1M331.4M
Operating Expenses308M396.8M520.3M554.7M350.2M
Depreciation & Amortization38M31.7M32.7M42.5M51.1M
EBITDA533M334.5M245.4M199M294.7M
EBITDA Margin45.8%29.6%21.9%17.7%27.3%
Operating Income492M378.1M229.6M174.2M329.3M
Operating Margin42.2%33.5%20.5%15.5%30.5%
Interest Income00000
Interest Expense046.2M107M112.3M107.3M
Other Income / Expenses3M(121.5M)(123.9M)(130M)(193M)
Income Before Tax495M256.6M105.7M44.2M136.3M
Pre-Tax Margin42.5%22.7%9.4%3.9%12.6%
Income Tax Expense80M33M35.3M(34.1M)40.9M
Net Income414.8M223.6M70.4M78.3M95.4M
Net Margin35.6%19.8%6.3%7.0%8.8%
EPS (Basic)7.313.921.231.361.64
EPS (Diluted)7.313.891.221.341.62
Weighted Avg Shares56.8M57.06M57.24M58.43M58.31M
Weighted Avg Shares (Diluted)56.8M57.06M57.76M58.33M58.92M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.